Biodesix, Inc. BDSX
8.53 USD -11.31 (-57.01%)
At closeNov 6, 2026, 7:55 PM EST
9.00 +0.47 +5.51%
After hours · Nov 6, 7:55 PM ET
7.99 Day range 13.03
5.46 52-week range 30.60
- YTD
- +25.44%
- 1 year
- +9.50%
News
benzinga.com Lake Street Maintains Buy on Biodesix, Lowers Price Target to $30 Lake Street analyst Thomas Flaten maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $40 to $30.
benzinga.com Gold Falls 1%; Charter Communications Shares Fall After Q3 Results U.S. stocks gained Friday, led by Nasdaq +1.5%, as jobs beat forecasts. Gogo and JFrog surged, while DraftKings and Biodesix plunged.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Nasdaq Jumps 400 Points; US Nonfarm Payrolls Top Estimates In October U.S. stocks were mixed: Nasdaq +1.75%, S&P +0.99%, Dow -0.21%, as October jobs beat forecasts; oil rose, while global markets mostly fell.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
benzinga.com Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook Biodesix shares fall after hours following third-quarter results and revised 2026 revenue guidance.
seekingalpha.com Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript
benzinga.com Biodesix Q3 2026 Earnings Call Transcript Biodesix (NASDAQ:BDSX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est Biodesix (NASDAQ:BDSX) lowers FY2026 sales outlook from $108.000 million-$114.000 million to $101.000 million-$103.000 million vs $111.817 million estimate.
globenewswire.com Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present…
benzinga.com Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis." Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a…
benzinga.com Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a…
benzinga.com TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40 TD Cowen analyst Dan Brennan maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $30 to $40.
benzinga.com Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects…